Hetero Labs in India has issued a recall of 87 lots of losartan potassium tablets because they contain the impurity, N-Nitroso-N-methyl-4-aminobutyric acid. This is the first recall resulting from the presence of NMBA.
The impurity is a known animal carcinogen, and may cause cancer in humans.
Hetero Labs’ losartan is packaged and sold by Camber Pharmaceuticals in the U.S.
This is the third impurity found in generic blood pressure medications. The first impurity was detected in the blood pressure drug valsartan in July, which started a string of recalls.
Read the full news release here.
More articles on pharmacy:
Viewpoint: It’s time for pharma to have its ‘tobacco moment’
Top 10 fatal or harmful prescribing errors
‘Wacky’ rebate system to blame for high patient drug prices, FDA chief says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.